Evidence map›Paper›PMID 38503487›Full record

ArticleHeart (British Cardiac Society)2024

Presence and utility of electrocardiographic abnormalities in long-term childhood cancer survivors.

Esmée C de Baat, Remy Merkx, Jan M Leerink, Coen Boerhout, Heleen J H van der Pal, Elvira C van Dalen, Jacqueline Loonen, Dorine Bresters, Eline van Dulmen-den Broeder, Margriet van der Heiden-van der Loo and 13 more

Open access · hybridAbstract read
In one paragraph

Article in Heart (British Cardiac Society), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 7 institutions in 4 countries.

Esmée C de BaatPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands e.c.debaat-2@prinsesmaximacentrum.nl.ORCID 0000-0003-2694-8783
Remy MerkxMedical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0002-9853-7257
Jan M LeerinkDepartment of Cardiology, Amsterdam UMC, Amsterdam, The Netherlands.
Coen BoerhoutDepartment of Cardiology, Amsterdam UMC, Amsterdam, The Netherlands.ORCID 0000-0003-1515-9623
Heleen J H van der PalPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Elvira C van DalenPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Jacqueline LoonenPediatric Hematology and Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
Dorine BrestersPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Eline van Dulmen-den BroederAmsterdam University Medical Centres, Amsterdam, The Netherlands.
Margriet van der Heiden-van der LooPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Marry M van den HeuvelPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Judith L KokPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Marloes LouwerensMedical Oncologist, Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Sebastian J C M M NeggersPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Cecline M RonckersUniversity Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Jop C TeepenPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Wim J E TissingPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Andrica C de VriesPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Livia KapustaDepartment of Paediatrics, Tel Aviv University, Tel Aviv, Israel.
Leontien C M KremerPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Annelies M C Mavinkurve-GroothuisPrincess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Wouter E M Kok *Department of Cardiology, Amsterdam UMC, Amsterdam, The Netherlands.
Elizabeth A M Feijen *Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.ORCID 0000-0001-8930-3160
Princess Máxima Center · NLAmsterdam University Medical Centers · NLErasmus MC · NLRadboud University Nijmegen · NLLeiden University Medical Center · NLBeatrix Kinderziekenhuis · NLJohannes Gutenberg University Mainz · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe assessed the prevalence and diagnostic value of ECG abnormalities for cardiomyopathy surveillance in childhood cancer survivors.

methodsIn this cross-sectional study, 1381 survivors (≥5 years) from the Dutch Childhood Cancer Survivor Study part 2 and 272 siblings underwent a long-term follow-up ECG and echocardiography. We compared ECG abnormality prevalences using the Minnesota Code between survivors and siblings, and within biplane left ventricular ejection fraction (LVEF) categories. Among 880 survivors who received anthracycline, mitoxantrone or heart radiotherapy, logistic regression models using least absolute shrinkage and selection operator identified ECG abnormalities associated with three abnormal LVEF categories (<52% in male/<54% in female, <50% and <45%). We assessed the overall contribution of these ECG abnormalities to clinical regression models predicting abnormal LVEF, assuming an absence of systolic dysfunction with a <1% threshold probability.

results16% of survivors (52% female, mean age 34.7 years) and 14% of siblings had major ECG abnormalities. ECG abnormalities increased with decreasing LVEF. Integrating selected ECG data into the baseline model significantly improved prediction of sex-specific abnormal LVEF (c-statistic 0.66 vs 0.71), LVEF <50% (0.66 vs 0.76) and LVEF <45% (0.80 vs 0.86). While no survivor met the preset probability threshold in the first two models, the third model used five ECG variables to predict LVEF <45% and was applicable for ruling out (sensitivity 93%, specificity 56%, negative predictive value 99.6%). Calibration and internal validation tests performed well.

conclusionA clinical prediction model with ECG data (left bundle branch block, left atrial enlargement, left heart axis, Cornell's criteria for left ventricular hypertrophy and heart rate) may aid in ruling out LVEF <45%.

Indexed as

Cancer SurvivorsElectrocardiographyStroke VolumeAdolescentAdultCardiomyopathiesChildChild, PreschoolCross-Sectional StudiesEchocardiographyFemaleHumansMaleNeoplasmsNetherlandsPredictive Value of TestsCardiomyopathiesElectrocardiographyEpidemiology

Identifiers

PMID38503487
PMCPMC11103333
OpenAlexW4392947617

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.